Document Detail


Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study.
MedLine Citation:
PMID:  23110867     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Multiplex assays such as xMAP have been proposed for the assessment of Alzheimer's disease (AD) biomarkers amyloid β 42 (Aβ(42)), tau (Tau), and phosphorylated tau (pTau) in cerebrospinal fluid (CSF). Here, we compared the traditional enzyme-linked immunosorbent assay (ELISA) and xMAP with respect to their: (1) absolute biomarker concentration, (2) ability to distinguish AD from nondemented subjects, (3) ability to monitor AD longitudinally, and (4) ability to predict progression from mild cognitive impairment (MCI) to AD. METHODS: We selected 68 AD, 62 MCI, and 24 nondemented subjects, performed clinical examinations, and obtained CSF at baseline and 2 years later. Aβ(42), Tau, and pTau were measured with both ELISA and xMAP. RESULTS: Biomarker levels differed considerably between the two assays, and the differences were concentration dependent. No differences were observed in ability to distinguish nondemented subjects from AD patients between ELISA (area under curve of 0.84 for Aβ(42), 0.79 for Tau, and 0.75 for pTau) and xMAP (area under curve of 0.82 for Aβ(42), 0.75 for Tau, and 0.73 for pTau), all P < .05. Increased Aβ(42) levels of AD patients at follow-up compared with baseline were detected with ELISA, whereas increased Tau levels for nondemented subjects and MCI patients were only detected with xMAP. The hazard ratios for progression from MCI to AD did not differ between the assays. CONCLUSION: Both ELISA and multiplex assays can be used to measure AD biomarker levels in CSF to support clinical diagnosis and predict progression from MCI to AD with similar accuracy. Importantly, the assays' output in absolute biomarker concentrations is remarkably different, and this discrepancy cannot be reconciled with simple correction factors.
Authors:
Wesley Jongbloed; Maartje I Kester; Wiesje M van der Flier; Robert Veerhuis; Philip Scheltens; Marinus A Blankenstein; Charlotte E Teunissen
Related Documents :
8182647 - Inclusion body myositis in association with rheumatoid arthritis.
10857797 - Antineutrophil cytoplasmic antibodies in patients with early rheumatoid arthritis: an e...
10343527 - Genotyping for disease associated hla dr beta 1 alleles and the need for early joint su...
6610047 - Hla antigens in palindromic rheumatism, nonerosive rheumatoid arthritis and classical r...
11755227 - Zonisamide has beneficial effects on parkinson's disease patients.
10399127 - Blood loss in duchenne muscular dystrophy: vascular smooth muscle dysfunction?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-27
Journal Detail:
Title:  Alzheimer's & dementia : the journal of the Alzheimer's Association     Volume:  -     ISSN:  1552-5279     ISO Abbreviation:  Alzheimers Dement     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-31     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101231978     Medline TA:  Alzheimers Dement     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Clinical Chemistry, Neurological Laboratory, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: w.jongbloed@vumc.nl.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mild cognitive impairment in a community sample: The Sydney Memory and Ageing Study.
Next Document:  The influence of insulin infusion on the metabolism of amyloid ? peptides in plasma.